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Abstract Hereditary diffuse gastric cancer (HDGC) is a
cancer susceptibility syndrome characterized by a high risk
of diffuse stomach cancer and lobular breast cancer. HDGC
is caused by germline mutations in the CDH1 gene
encoding the E-cadherin which is a member of the trans-
membrane glycoprotein family responsible for calcium-
dependent, cell-to-cell adhesion and plays a fundamental
role in the maintenance of cell differentiation and the
normal architecture of epithelial tissues. Mutations in the
CDH1 gene are detected in 30–46% of families that fulﬁl
strong clinical criteria for HDGC and in about 11% of
families fulﬁlling the modiﬁed criteria. In the present
study, we investigated germline mutations in the CDH1
gene in Polish patients with HDGC. The entire coding
sequence of CDH1 gene was analyzed by sequencing in 86
Polish cancer patients from families fulﬁlling the modiﬁed
criteria of HDGC. We found several silent mutations
including one common variant (c.2076T[C) present in 56
patients, and three rare variants (c.2253C[T, c.1896C[T,
c.2634C[T) detected in 2 patients. In addition, we found
four rare sequence variants of unknown signiﬁcance
localized in introns. We did not detect any deleterious
mutations of the CDH1 gene. CDH1 gene mutations are not
present in Polish families with HDGC deﬁned by the
modiﬁed clinical criteria. Further studies of families with
HDGC matching the restrictive criteria for HDGC are
needed.
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Abbreviations
CDH1 gene E-cadherin gene
IGCLC Gastric Cancer Linkage Consortium
HDGC Hereditary Diffuse Gastric Cancer
DGC Diffuse Gastric Cancer
GC Gastric Cancer
LBC Lobular Breast Cancer
FDGC Familial Diffuse Gastric Cancer
FGC Familial Gastric Cancer
EOGC Early Onset Gastric Cancer
PCR Polymerase Chain Reaction
MRI Magnetic Resonance Imaging
HGVS Human Genome Variation Society,
http://www.hgvs.org/
Introduction
The E-cadherin is a member of the transmembrane glyco-
protein family responsible for calcium-dependent, cell-
to-cell adhesion and plays a fundamental role in the
maintenance of cell differentiation and the normal archi-
tecture of epithelial tissues [1–7]. The protein is encoded
by the CDH1 gene which is located on chromosome
16q22.1 and consists of 16 exons. Mutations in CDH1 gene
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DOI 10.1007/s10689-010-9381-2are known to be associated with Hereditary Diffuse Gastric
Cancer syndrome (HDGC) [8–16] and also with lobular
breast cancer [17–19]. The HDGC has been deﬁned in
1999 by International Gastric Cancer Linkage Consortium
(IGCLC) as two or more documented cases of DGC in ﬁrst
or second degree relatives, including at least one case of
DGC diagnosed before the age of 50, or three or more
documented cases of DGC in ﬁrst or second degree rela-
tives diagnosed at any age [9, 10]. Among patients that
fulﬁll the above clinical criteria about 30–46% of cases
carry a mutation in the CDH1 gene [11, 15, 20–22].
Afterwards the IGCLC criteria have been modiﬁed e.g.
including cases diagnosed with lobular breast cancer or
signet-ring carcinoma of the colon [12]. The new modiﬁed
criteria were as follow: (1) two or more documented cases
of DGC in ﬁrst-degree relatives with at least one diagnosed
before age 50 years; (1A) two or more cases of GC with at
least 1 documented DGC diagnosed before age 50 years;
(2) three or more documented cases of DGC in ﬁrst-degree
relatives with diagnoses at any age; (2A) three or more
cases of GC, diagnosed at any age, with at least one doc-
umented case of DGC; (3) isolated individual diagnosed
with DGC at less than 45 years of age; (4) isolated indi-
vidual diagnosed with both DGC and lobular breast cancer
(no other criteria met); (5) one family member diagnosed
with DGC and another with lobular breast cancer (no other
criteria met); (6) one family member diagnosed with DGC
and another with signet-ring carcinoma of the colon (no
other criteria met). It has been shown that among patients
fulﬁlling the modiﬁed criteria 11% carry CDH1 mutation
[12–14].
Patients with germline mutations in the CDH1 have a
high risk of developing diffuse gastric cancer and female
carriers are at high risk of lobular breast cancer [17–19].
The estimated penetrance of CDH1 mutations is 70–80%
for stomach cancer [8, 15, 22, 23] and 39–52% for lobular
breast cancer [15, 23]. Because of high penetrance of
CDH1 mutations and almost 100% mortality of patients
with symptomatic DGC prophylactic total gastrectomy
during the second decade of life is recommended for CDH1
mutation carriers [22, 24–26]. Referring to updated con-
sensus guidelines for clinical management of HDGC in
female carriers surveillance including monthly breast self
examination starting at age 35, annual mammogram and
breast MRI is recommended [26]. Additionally, in families
in which colon cancer was reported enhanced screening
with colonoscopy beginning at age 40 or 10 years younger
than the youngest diagnosis of colon cancer and repeated at
intervals of 3–5 years should be considered [26].
Given the complexity and high mortality of HDGC, not
only with regard to the management of the DGC, but also
with regard to the risk for other related cancers such as
lobular breast cancer or colon cancer, it is very important to
identify asymptomatic carriers of CDH1 mutations in order
to apply the appropriate surveillance.
In the current study we sought to determine prevalence
of CDH1 mutations in Polish families with diffuse gastric
cancer.
Materials and methods
Patients
For analysis of CDH1 gene 86 Polish patients from fami-
lies fulﬁlling the modiﬁed criteria of HDGC were selected.
Among these cases 82 were affected by DGC, two cases
were diagnosed with lobular breast cancer and two with
colon cancer. Only families with GC diagnosed in ﬁrst and
second degree relatives were included to this study. The
characteristic of tested families including mean age at
stomach cancer diagnosis is presented in the Table 1.
Patients were invited to participate in this study either in
person during their hospital stay in participating hospitals
throughout Poland or through a mailed invitation. Patients
who responded to the personal or mailed invitation were
invited to the local study center for an interview. During the
interview the goals of the study were explained, informed
consent was obtained, genetic counseling was given and a
blood sample was taken for DNA analysis. A detailed
family history of gastric cancer in ﬁrst- and second-degree
relatives was taken and the medical record and/or pathology
report were reviewed and forwarded to the study center in
Szczecin. Information was recorded on age at diagnosis and
cancer pathology. The study was approved by the Ethics
Committee of the Pomeranian Medical University in
Szczecin, Poland.
Sequencing
Peripheral blood samples from 86 probands were obtained
for genomic DNA isolation. DNA was isolated using a
standard procedure [27]. The entire coding sequence of
CDH1 gene and intron/exon splice sites, was ampliﬁed in
PCR reactions using primers and conditions described
previously [16]. After puriﬁcation, PCR products were
analysed on an ABI 377 DNA Sequencer according to
manufacturer’s procedure.
Results and discussion
This is the ﬁrst study of CDH1 mutations in the Polish
population, in which we screened 86 patients with HDGC.
We found four different silent mutations: one common
(c.2076T[C) and three rare (c.2253C[T, c.1896C[T,
606 A. Jakubowska et al.
123c.2634C[T) variants. In addition, we found ﬁve different
sequence variants of unknown signiﬁcance localized in
introns (Table 2). We did not detect any pathogenic
mutations in the CDH1 gene.
Germline mutations in CDH1 gene were originally
reported in three Maori families with aggregation of diffuse
gastric cancer [8]. Since this report, several studies have
investigated the role of CDH1 mutations in gastric cancer in
different ethnic groups [8–22]. It has been reported that
CDH1 mutations underlie approximately 40% of families
fulﬁlling the strong IGCLC criteria for hereditary diffuse
gastric cancer (HDGC). However, the criteria for HDGC
deﬁned by IGCLC require strong family history with
all documented cases of diffuse gastric cancer what refers to
small number of all patients affected with gastric cancer.
Therefore, CDH1 gene has been screened in gastric cancer
patients fulﬁlling less restrictive, modiﬁed criteria of famil-
ial diffuse gastric cancer (FDGC–families with aggregation
of gastric cancer and index cases with diffuse gastric cancer
but not fulﬁlling the IGCLC criteria for HDGC), familial
gastric cancer (FGC–families with aggregation of gastric
cancer, but without histology available on the tumors) and
early-onset gastric cancer (EOGC–patients with isolated
diffuse gastric cancer diagnosed before age 45 years) [9].
CDH1 mutations have been found in 11% (21/192) of
familieswithFDGCandalmost7%(17/254)ofpatientswith
EOGC [11].
In the present study we screened a relatively large series
of 86 cases with HDGC fulﬁlling the modiﬁed criteria
(FDGC, EOGC), but we did not ﬁnd any pathogenic
mutations in the CDH1 gene. We performed a sensitive
exon by exon sequencing of the entire gene including sur-
rounding intronic sequences. With this method we are able
to detect all small intragenic mutations which are the most
common mutations observed in the CDH1 gene [8–22].
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Table 2 CDH1 variants detected in 86 Polish patients with HDGC
CDH1 variant
a Number of carriers
c.1896C[T (p.=) 1
b
c.2076T[C (p.=) 56
c.2253C[T (p.=) 1
c.2634C[T (p.=) 1
b
c.1-44A/G 7
c.172?6T/C 11
c.655?10C/G 2
c.1836-46A/G 1
c.1836-13T/C 14
a Description of detected variants according to the HGVS recom-
mendations; (p.=) indicates lack of effect on protein level–silent
mutation
b Patient with both detected variants
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123Recently large genomic deletions in CDH1 gene have been
found in patients from HDGC families. In the study of 160
patients from families fulﬁlling the restrictive criteria
HDGC 67 (42%) point or small frameshift mutations and 6
(4%) large genomic deletions in CDH1 gene were detected
[20]. This indicates that large genomic rearrangements
constitute only a small proportion of CDH1 mutations
(*8%). It is unlikely that the negative result of our study is
due to low sensitivity of methods used for mutation
screening.
In summary, results of our study show that CDH1
mutations do not contribute to diffuse gastric cancer in
Poland, however, taking into account limitations of our
study which are: less restrictive criteria of gastric cancer
patients selection and lack of analysis for large genomic
deletions, further studies of HDGC in Polish population are
needed.
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